Ono Pharma licenses Biohaven IgG degraders for Japan, South Korea, Taiwan and ASEAN
BHVN•Ono Pharma signed an exclusive license agreement with Biohaven to develop and commercialize IgG degraders in Japan, South Korea, Taiwan and ASEAN. Ono will pay $80 million upfront, a $20 million milestone payment and royalties of approximately 20% on net sales.
1. License agreement terms
Ono Pharma announced an exclusive license agreement with Biohaven to develop and commercialize IgG degraders in Japan, South Korea, Taiwan and ASEAN. Ono will pay Biohaven $80 million upfront and $20 million upon achievement of a milestone, plus royalties of approximately 20% on net sales.
